ThinkSabio

$CYTK

$64.00▲ +1.6% YTD

11 SEC 13D/G filings tracked · Last updated Nov 2, 2026

Filing History
News
CYTK ▲ +1.6% - Cytokinetics, Incorporated
CP $64.00▲ +1.6%Nov 2, 2026 · ThinkSabio Blog

$CYTK - Cytokinetics Announces Three Upcoming Presentations at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions Held in Coll…

News
CYTK ▼ -1.7% - Cytokinetics, Incorporated
CP $62.86▲ -1.7%Oct 21, 2026 · ThinkSabio Blog

$CYTK - Cytokinetics to Announce Third Quarter Results on November 4, 2026…

News
CYTK ▲ +0.8% - Cytokinetics, Incorporated
CP $62.49▲ +0.8%Oct 19, 2026 · ThinkSabio Blog

$CYTK - Cytokinetics Announces Health Canada Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Ca…

News
CYTK ▼ -0.2% - Cytokinetics, Incorporated
CP $62.77▲ -0.2%Oct 12, 2026 · ThinkSabio Blog

$CYTK - Cytokinetics Announces Additional Data from ACACIA-HCM Presented at the HFSA Annual Scientific Meeting 2026…

News
CYTK ▼ -1.5% - Cytokinetics, Incorporated
CP $60.18▲ -1.5%Oct 8, 2026 · ThinkSabio Blog

$CYTK RBC Capital analyst Leonid Timashev raised the firm's price target on Cytokinetics to $113 from $112 and keeps an Outperform rating on the share…

News
CYTK ▲ +0.0% - Cytokinetics, Incorporated
CP $65.62▲ +0.0%Oct 2, 2026 · ThinkSabio Blog

$CYTK - Cytokinetics Announces Four Upcoming Presentations at the HFSA Annual Scientific Meeting 2026…

News
CYTK ▲ +0.4% - Cytokinetics, Incorporated
CP $65.90▲ +0.4%Sep 30, 2026 · ThinkSabio Blog

$CYTK - Cytokinetics Launches ASPEN-HCM: A Real-World Study Evaluating MYQORZO® (aficamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy…

News
CYTK ▲ +0.6% - Cytokinetics, Incorporated
CP $71.93▲ +0.6%Sep 2, 2026 · ThinkSabio Blog

$CYTK - Cytokinetics to Participate in September Investor Conferences…

News
CYTK ▼ -6.3% - Cytokinetics, Incorporated
CP $73.00▲ -6.3%Aug 29, 2026 · ThinkSabio Blog

$CYTK - Cytokinetics Announces Additional Results from ACACIA-HCM and MAPLE-HCM Presented in Late Breaking Clinical Trial Session at the European Soci…

SEC 13D/G
CYTK - Cytokinetics, Incorporated - SEC Filing Update (13-AUG-2026) | ThinkSabio - Stocks Simplified
$73.45▲ 18.91%Aug 13, 2026 · ThinkSabio Blog

$CYTK SEC 13D/G institutional ownership filing. Healthcare sector. SEC Filing Update: #CYTK Cytokinetics, Incorporated : $73.45 Sector: Healthcare | Y…

SEC 13D/G
$CYTK SEC Filing Update (08-JUL-2026) | ThinkSabio - Stocks Simplified
$84.25▲ 36.39%Jul 8, 2026 · ThinkSabio Blog

$CYTK SEC 13D/G institutional ownership filing. Healthcare sector. SEC Filing Update: #CYTK : $84.25 Sector: Healthcare | YTD: 🔼+ 36.39% The SEC discl…